litlas
ログインアカウント作成

Jonathan D. Cheng

2000–2022 年に発表

47
論文数
24,798
被引用数
45
h 指数
47
i10 指数

被引用数

Jonathan D. Cheng の年別被引用数1945 年: 被引用 1 件1995 年: 被引用 2 件2002 年: 被引用 1 件2003 年: 被引用 10 件2004 年: 被引用 6 件2005 年: 被引用 14 件2006 年: 被引用 22 件2007 年: 被引用 15 件2008 年: 被引用 28 件2009 年: 被引用 37 件2010 年: 被引用 29 件2011 年: 被引用 37 件2012 年: 被引用 66 件2013 年: 被引用 53 件2014 年: 被引用 63 件2015 年: 被引用 93 件2016 年: 被引用 150 件2017 年: 被引用 272 件2018 年: 被引用 363 件2019 年: 被引用 1,274 件2020 年: 被引用 1,713 件2021 年: 被引用 1,845 件2022 年: 被引用 1,485 件2023 年: 被引用 1,044 件2024 年: 被引用 1,510 件2025 年: 被引用 682 件2026 年: 被引用 18 件1946〜1994 年は被引用が無いため表示していません1996〜2001 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 3,308 件、この内訳の 24.5%中国: 引用元論文 2,473 件、この内訳の 18.3%ドイツ: 引用元論文 702 件、この内訳の 5.2%イギリス: 引用元論文 624 件、この内訳の 4.6%イタリア: 引用元論文 603 件、この内訳の 4.5%日本: 引用元論文 528 件、この内訳の 3.9%フランス: 引用元論文 485 件、この内訳の 3.6%カナダ: 引用元論文 426 件、この内訳の 3.1%スペイン: 引用元論文 414 件、この内訳の 3.1%韓国: 引用元論文 345 件、この内訳の 2.6%オランダ: 引用元論文 341 件、この内訳の 2.5%オーストラリア: 引用元論文 337 件、この内訳の 2.5%
0%24.5%その他 21.6%

機関

分野

  • Medicine75.6%
  • Biochemistry, Genetics and Molecular Biology14.4%
  • Immunology and Microbiology7%
  • Engineering1.1%
  • Neuroscience0.5%
  • Mathematics0.2%
  • その他1.2%

トピック

  • Cancer Immunotherapy and Biomarkers18.1%
  • Immunotherapy and Immune Responses5.4%
  • Head and Neck Cancer Studies4%
  • Ferroptosis and cancer prognosis3.5%
  • CAR-T cell therapy research3.5%
  • Immune Cell Function and Interaction3.1%
  • その他62.4%

共著者

全論文

検索で開く
  1. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

    著者: Barbara Burtness, Kevin J. Harrington, Richard Greil, Denis Soulières, Makoto Tahara, Gilberto de Castro, Amanda Psyrri, Neus Basté, Prakash Neupane, Åse Bratland, Thorsten Fuereder, Brett Hughes, Ricard Mesı́a, Nuttapong Ngamphaiboon, Tamara Rordorf, Wan Zamaniah Wan Ishak, Ruey‐Long Hong, René González Mendoza, Ananya Roy, Yayan Zhang, Burak Gümüşçü, Jonathan D. Cheng, Fan Jin, Danny Rischin, Guillermo Lerzo, Marcelo Tatangelo, Mirta Varela, Juan José Zarbá, Michael Boyer, Hui Gan, Bo Gao, Brett Hughes, Girish Mallesara, Danny Rischin, Anne L. Taylor, Martin Burian, Thorsten Fuereder, Richard Greil, Carlos H. Barrios, Dalvaro Oliveira de Castro Junior, Gilberto de Castro, Fábio Franke, Gustavo Girotto, Iane Pinto Figueiredo Lima, Ulisses Ribaldo Nicolau, Gustavo Dix Junqueira Pinto, Lucas Vieira dos Santos, Ana-Paula Victorino, Neil Chua, Félix Couture, Richard Gregg, Aaron R. Hansen, John Hilton, Joy McCarthy, Denis Soulières, Rodrigo Ascuí, Pablo Gonzalez, Luis J. Villanueva-Rivera, Marco Torregroza, Ángela R. Zambrano, Petra Holečková, Zdeněk Král, Bohuslav Melichar, Prausova Jana, Milan Vošmik, Maria Andersen, Niels Gyldenkerne, Hannes Jürgens, Kadri Putnik, Petri Reinikainen, Viktor Gruenwald, Simon Laban, Gerasimos Aravantinos, Ioannis Boukovinas, Vassilis Georgoulias, Amanda Psyrri, D.L.W. Kwong, Yousuf Al-Farhat, Tibor Csőszi, József Erfán, Geza Horvai, László Landherr, Éva Remenár, Ágnes Ruzsa, Judit Szota, Salem Billan, Iris Gluck, Orit Gutfeld, Aron Popovtzer, Marco Benasso, Simona Bui, Vittorio Ferrari, Lisa Licitra, Franco Nolè, Takashi Fujii, Yasushi Fujimoto, Nobuhiro Hanai, Hiroki Hara, Koji Matsumoto, Kenji Mitsugi ほか 119 名 - The Lancet 2019 被引用: 3,211

  2. IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade

    著者: Mark Ayers, Jared Lunceford, Michael Nebozhyn, Erin Murphy, Andrey Loboda, David R. Kaufman, Andrew Albright, Jonathan D. Cheng, Shijun Kang, Veena Shankaran, Sarina A. Piha‐Paul, Jennifer H. Yearley, Tanguy Y. Seiwert, Antoni Ribas, Terrill K. McClanahan - Journal of Clinical Investigation 2017 被引用: 3,872

  3. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy

    著者: Răzvan Cristescu, Robin Mogg, Mark Ayers, Andrew Albright, Erin Murphy, Jennifer H. Yearley, Xinwei Sher, Xiao Qiao Liu, Hongchao Lu, Michael Nebozhyn, Chunsheng Zhang, Jared Lunceford, Andrew K. Joe, Jonathan D. Cheng, Andrea L. Webber, Nageatte Ibrahim, Elizabeth R. Plimack, Patrick A. Ott, Tanguy Y. Seiwert, Antoni Ribas, Terrill K. McClanahan, Joanne E. Tomassini, Andrey Loboda, David R. Kaufman - Science 2018 被引用: 2,380

  4. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer

    著者: Seung Tae Kim, Răzvan Cristescu, Adam J. Bass, Kyoung‐Mee Kim, Justin I. Odegaard, Kyung Kim, Xiao Qiao Liu, Xinwei Sher, Hun Jung, Mi-Jin Lee, Sujin Lee, Se Hoon Park, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Hyuk Lee, Min Gew Choi, AmirAli Talasaz, Peter Kang, Jonathan D. Cheng, Andrey Loboda, Jeeyun Lee, Won Ki Kang - Nature Medicine 2018 被引用: 1,717

  5. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

    著者: Ezra E.W. Cohen, Denis Soulières, Christophe Le Tourneau, José Dinis, Lisa Licitra, Myung‐Ju Ahn, Ainara Soria, Jean‐Pascal Machiels, Nicolas Mach, Ranee Mehra, Barbara Burtness, Pingye Zhang, Jonathan D. Cheng, Ramona F. Swaby, Kevin J. Harrington, Mirelis Acosta-Rivera, Douglas R. Adkins, Morteza Aghmesheh, Myung‐Ju Ahn, Mario Airoldi, Eduardas Aleknavičius, Yousuf Al-Farhat, Alain P. Algazi, Salah Almokadem, Anna Alyasova, Jessica R. Bauman, Marco Benasso, Alfonso Berrocal, Victoria Bray, Barbara Burtness, Francesco Caponigro, Ana Castro, Terrence P. Cescon, Kelvin Chan, Arvind Chaudhry, Bruno Chauffert, Ezra E.W. Cohen, Tibor Csőszi, Jan Paul de Boer, Jean‐Pierre Delord, Andreas Dietz, José Dinis, Charlotte Dupuis, Laurence Digue, József Erfán, Yolanda Escobar Alvarez, Mererid Evans, Mary J. Fidler, Martin Förster, Signe Friesland, Apar Kishor Ganti, Lionnel Geoffrois, Clíona Grant, Viktor Gruenwald, Kevin J. Harrington, Thomas K. Hoffmann, Geza Horvai, Arturas Inčiūra, Raymond Woo-Jun Jang, Petra Jankowska, Antonio Jimeno, Mano Joseph, Alejandro Juárez Ramiro, Bogusława Karaszewska, Andrzej Kawecki, Ulrich Keilholz, Ulrich Keller, Sung‐Bae Kim, Judit Kocsis, Nuria Kotecki, Mark Kozloff, J. Lambea, László Landherr, Yuri Lantsukhay, Sergey Lazarev, Lip Way Lee, Christophe Le Tourneau, Lisa Licitra, Igor Lifirenko, Nicolas Mach, Danko Martincic, О. В. Маторин, Margaret McGrath, Jean‐Pascal Machiels, Ranee Mehra, Krzysztof Misiukiewicz, John C. Morris, Ф. Ф. Муфазалов, Jiaxin Niu, Devraj Srinivasan, Pedro Pérez Segura, Daniel Rauch, Maria Leonor Ribeiro, Cristina P. Rodriguez, Frédéric Rolland, Antonio Russo, Ágnes Ruzsa, Frederico Sanches, Sangwon Shin, Mikhail Shtiveland ほか 13 名 - The Lancet 2018 被引用: 1,697

  6. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial

    著者: Tanguy Y. Seiwert, Barbara Burtness, Ranee Mehra, Jared Weiss, Raanan Berger, Joseph P. Eder, Karl Heath, Terrill K. McClanahan, Jared Lunceford, Christine K. Gause, Jonathan D. Cheng, Laura Q.M. Chow - The Lancet Oncology 2016 被引用: 1,740

  7. Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study

    著者: Rita Nanda, Laura Q.M. Chow, Elizabeth Claire Dees, Raanan Berger, Shilpa Gupta, Ravit Geva, Lajos Pusztai, Kumudu Pathiraja, Gursel Aktan, Jonathan D. Cheng, Vassiliki Karantza, Laurence Buisseret - Journal of Clinical Oncology 2016 被引用: 1,473

  8. PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer

    著者: Jennifer H. Yearley, Christopher J. Gibson, Ni Yu, Christina Moon, Erin Murphy, Jonathan Juco, Jared Lunceford, Jonathan D. Cheng, Laura Q.M. Chow, Tanguy Y. Seiwert, Masahisa Handa, Joanne E. Tomassini, Terrill K. McClanahan - Clinical Cancer Research 2017 被引用: 604

  9. Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012

    著者: Ranee Mehra, Tanguy Y. Seiwert, Shilpa Gupta, Jared Weiss, Iris Gluck, Joseph P. Eder, Barbara Burtness, Makoto Tahara, Bhumsuk Keam, Hyunseok Kang, Kei Muro, Ravit Geva, Hyun Cheol Chung, Chia‐Chi Lin, Deepti Aurora-Garg, Archana Ray, Kumudu Pathiraja, Jonathan D. Cheng, Laura Q.M. Chow, Robert I. Haddad - British Journal of Cancer 2018 被引用: 456

  10. Extended Structure–Activity Relationship and Pharmacokinetic Investigation of (4-Quinolinoyl)glycyl-2-cyanopyrrolidine Inhibitors of Fibroblast Activation Protein (FAP)

    著者: Koen Jansen, Leen Heirbaut, Robert Verkerk, Jonathan D. Cheng, Jurgen Joossens, Paul Cos, Louis Maes, Anne‐Marie Lambeir, Ingrid De Meester, Koen Augustyns, Pieter Van der Veken - Journal of Medicinal Chemistry 2014 被引用: 280

  11. Selective Inhibitors of Fibroblast Activation Protein (FAP) with a (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine Scaffold

    著者: Koen Jansen, Leen Heirbaut, Jonathan D. Cheng, Jurgen Joossens, O.V. Ryabtsova, Paul Cos, Louis Maes, Anne‐Marie Lambeir, Ingrid De Meester, Koen Augustyns, Pieter Van der Veken - ACS Medicinal Chemistry Letters 2013 被引用: 260

  12. Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1–Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study

    著者: Chiun Hsu, Se‐Hoon Lee, Samuel Ejadi, Caroline Even, Roger B. Cohen, Christophe Le Tourneau, Janice M. Mehnert, Alain P. Algazi, Emilie M.J. van Brummelen, Sanatan Saraf, Pradeep Thanigaimani, Jonathan D. Cheng, Aaron R. Hansen - Journal of Clinical Oncology 2017 被引用: 471

  13. Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study

    著者: Joshua Bauml, Tanguy Y. Seiwert, David G. Pfister, Francis P. Worden, Stephen V. Liu, Jill Gilbert, Nabil F. Saba, Jared Weiss, Lori J. Wirth, Ammar Sukari, Hyunseok Kang, Michael K. Gibson, Erminia Massarelli, Steven Powell, Amy Meister, Xinxin Shu, Jonathan D. Cheng, Robert I. Haddad - Journal of Clinical Oncology 2017 被引用: 652

  14. Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort

    著者: Laura Q.M. Chow, Robert I. Haddad, Shilpa Gupta, Amit Mahipal, Ranee Mehra, Makoto Tahara, Raanan Berger, Joseph P. Eder, Barbara Burtness, Se‐Hoon Lee, Bhumsuk Keam, Hyunseok Kang, Kei Muro, Jared Weiss, Ravit Geva, Chia‐Chi Lin, Hyun Cheol Chung, Amy Meister, Marisa Dolled‐Filhart, Kumudu Pathiraja, Jonathan D. Cheng, Tanguy Y. Seiwert - Journal of Clinical Oncology 2016 被引用: 859

  15. Phase II trial of single agent Val-boroPro (talabostat) inhibiting fibroblast activation protein in patients with metastatic colorectal cancer

    著者: Kalyani Narra, Stefanie Mullins, Hyung-Ok Lee, Brenda Strzemkowski-Brun, K. Magalong, Victoria J. Christiansen, Patrick A. McKee, Brian L. Egleston, Steven J. Cohen, Louis M. Weiner, Neal J. Meropol, Jonathan D. Cheng - Cancer Biology & Therapy 2007 被引用: 270

  16. Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced, PD-L1–positive papillary or follicular thyroid cancer

    著者: Janice M. Mehnert, Andréa Varga, Marcia S. Brose, Rahul Aggarwal, Chia‐Chi Lin, Amy Prawira, Filippo de Braud, Kenji Tamura, Toshihiko Doi, Sarina A. Piha‐Paul, Jill Gilbert, Sanatan Saraf, Pradeep Thanigaimani, Jonathan D. Cheng, Bhumsuk Keam - BMC Cancer 2019 被引用: 221

  17. Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study

    著者: Kevin J. Harrington, Anthony Kong, Nicolas Mach, Jason Chesney, Beatriz Castelo Fernández, Danny Rischin, Ezra E.W. Cohen, Hoi-Shen Radcliffe, Burak Gümüşçü, Jonathan D. Cheng, Wendy Snyder, Lillian L. Siu - Clinical Cancer Research 2020 被引用: 108

  18. Clinical Implications of Fibroblast Activation Protein in Patients with Colon Cancer

    著者: Leonard R. Henry, Hyung‐Ok Lee, John S. Lee, Andres J. Klein–Szanto, Perry Watts, Eric A. Ross, Wen‐Tien Chen, Jonathan D. Cheng - Clinical Cancer Research 2007 被引用: 361

  19. Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer

    著者: Janice M. Mehnert, Anshuman Panda, Judy Zhong, Kim M. Hirshfield, Sherri Damare, Katherine Lane, Levi Sokol, Mark N. Stein, Lorna Rodriguez-Rodriquez, Howard L. Kaufman, Siraj M. Ali, Jeffrey S. Ross, Dean C. Pavlick, Gyan Bhanot, Eileen White, Robert S. DiPaola, Ann Lovell, Jonathan D. Cheng, Shridar Ganesan - Journal of Clinical Investigation 2016 被引用: 385

  20. FAP-overexpressing fibroblasts produce an extracellular matrix that enhances invasive velocity and directionality of pancreatic cancer cells

    著者: Hyung‐Ok Lee, Stefanie Mullins, Janusz Franco‐Barraza, Matthildi Valianou, Edna Cukierman, Jonathan D. Cheng - BMC Cancer 2011 被引用: 295

  21. Fibroblast Activation Protein and Its Relationship to Clinical Outcome in Pancreatic Adenocarcinoma

    著者: Steven J. Cohen, R. Katherine Alpaugh, Irma Palazzo, Neal J. Meropol, André Rogatko, Zhiheng Xu, John P. Hoffman, Louis M. Weiner, Jonathan D. Cheng - Pancreas 2008 被引用: 240

  22. Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma

    著者: Roger B. Cohen, Jean‐Pierre Delord, Toshihiko Doi, Sarina A. Piha‐Paul, Stephen V. Liu, Jill Gilbert, Alain P. Algazi, Silvia Damian, Ruey‐Long Hong, Christophe Le Tourneau, Daphne Day, Andréa Varga, Elena Élez, John M. Wallmark, Sanatan Saraf, Pradeep Thanigaimani, Jonathan D. Cheng, Bhumsuk Keam - American Journal of Clinical Oncology 2018 被引用: 206

  23. Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma

    著者: Robert I. Haddad, Tanguy Y. Seiwert, Laura Q.M. Chow, Shilpa Gupta, Jared Weiss, Iris Gluck, Joseph P. Eder, Barbara Burtness, Makoto Tahara, Bhumsuk Keam, Hyunseok Kang, Kei Muro, Andrew Albright, Robin Mogg, Mark Ayers, Lingkang Huang, Jared Lunceford, Răzvan Cristescu, Jonathan D. Cheng, Ranee Mehra - Journal for ImmunoTherapy of Cancer 2022 被引用: 96

  24. Complete Response to Neoadjuvant Chemoradiotherapy in Esophageal Carcinoma Is Associated With Significantly Improved Survival

    著者: Adam C. Berger, Jeffrey M. Farma, Walter J. Scott, Gary M. Freedman, Louis M. Weiner, Jonathan D. Cheng, Hao Wang, Melvyn Goldberg - Journal of Clinical Oncology 2005 被引用: 518